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Abstract
 
Pax5 activity is enhanced in activated B cells and is essential for class switch recombination
(CSR). We show that inhibitor of differentiation (Id)2 suppresses CSR by repressing the
gene expression of activation-induced cytidine deaminase (AID), which has been shown to
be indispensable for CSR. Furthermore, a putative regulatory region of AID contains E2A-
and Pax5-binding sites, and the latter site is indispensable for AID gene expression. Moreover,
the DNA-binding activity of Pax5 is decreased in Id2-overexpressing B cells and enhanced
in Id2
 
 
 
/
 
 
 
 B cells. The kinetics of Pax5, but not E2A, occupancy to AID locus is the same as
AID expression in primary B cells. Finally, enforced expression of Pax5 induces AID tran-
scription in pro–B cell lines. Our results provide evidence that the balance between Pax5 and
Id2 activities has a key role in AID gene expression.
Key words: B cell activation • class switch recombination • chromatin immunoprecipitation • 
histone acetylation • transcription
 
Introduction
 
Inhibitor of differentiation (Id) proteins play regulatory
roles in the coordination of proliferation and differentiation
(1, 2). They regulate differentiation through sequestration
of basic helix-loop-helix transcription factors, so-called E
proteins. On the other hand, Id proteins have also been
shown to interact with other families of transcription factors,
such as Pax and Ets proteins, and inhibit their DNA-binding
functions (3, 4). These observations suggest that Id proteins
play a more widespread regulatory role in cell differentiation
and function. E2A and Pax5 are essential for the normal
development of B cells (5). B cell differentiation is com-
pletely blocked in mice deficient for either of these factors
(5–7). Several studies have suggested another essential role
of E2A and Pax5 in mature B cell function (8, 9). In acti-
vated B cells, the levels of E2A protein and Pax5 transcript
are highly augmented (9, 10). Furthermore, enforced expres-
sion of Id2, an inhibitor of E2A, or Blimp1, a repressor of
Pax5, completely blocks class switch recombination (CSR)
(11). Recent studies demonstrated that activation-induced
cytidine deaminase (AID) is indispensable for somatic hyper-
mutation (SHM) and CSR of immunoglobulin genes (12).
These processes result in the production of high affinity
antibodies against the immunizing antigen and modifica-
tion of effector functions of antibodies (13). On the other
hand, little is known about a possible inhibitory system for
CSR that prevents an over-response of B cells. Here we
show that enforced expression of Id2 reduced AID expression
and inhibited CSR. By comparing human and murine se-
quences, we found a strikingly homologous region within
400 bp upstream of the AID gene in which there is a Pax5-
binding site that is indispensable for AID gene expression.
Moreover, a Pax5-containing DNA-binding complex at
the AID promoter was reduced by Id2 overexpression and
enhanced in Id2
 
 
 
/
 
 
 
 B cells. Furthermore, we found that
Pax5 was recruited to the AID locus after 2 d of stimulation
of B cells in vitro, at which time AID transcription was
initiated. Finally, we demonstrated that enforced expression of
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Pax5 but not E2A induced endogenous AID gene expres-
sion in pro–B-like cell lines. This effect was cancelled by
additional introduction of Id2. Our results provide evi-
dence that Id2 plays an important role in modulating Pax5
activity in regulation of AID expression that is functionally
antagonized by Id2. This result further suggests a funda-
mental role in differentiation by antagonizing several sets of
master gene activities.
 
Materials and Methods
 
Mice.
 
Id2
 
 
 
/
 
 
 
 mice on the 129/Sv genetic background were
maintained in specific pathogen-free conditions and used at 7–10
wk of age.
 
Cell Lines.
 
The pro–B cell line BaF/3 and the murine B cell
line M12 were cultured in RPMI1640 medium containing 10%
FBS and 50 
 
 
 
M 2-mercaptoethanol with mouse IL-3 (BaF/3) or
without IL-3 (M12). IL-3 was prepared as described previously
(14). Phoenix Eco cells (15) were cultured according to the pro-
tocol at http://www.uib.no/mbi/nolan/NL-phnxr.html.
 
Plasmids.
 
pcDNA-Pax5 and pcDNA-E47 were constructed
replacing the fragment from pCXN2-Pax5, pCMVE47 (16, 17)
into the pcDNA3 vector. To generate pMX-IRES-hCD4, the
IRES-GFP fragment of pMX-IRES-GFP was replaced by the
IRES-hCD4 fragment (Miltenyi Biotech). Id2, Pax5, and E47
cDNAs were cloned into pMX-IRES-hCD4. A BssHII site was
introduced into the multiple cloning site of pGL3 basic vector
(Promega).
 
Retrovirus Preparation and Infection.
 
Retroviruses were pro-
duced by transfecting pMX plasmids into the ecotropic Phoenix
packaging cell line (15). After overnight stimulation with LPS,
purified splenic B cells (18) were spin infected with the virus-
containing supernatant in the presence of 10 
 
 
 
g/ml DOTAP and
cultured with fresh complete RPMI medium plus cytokines (9).
 
Primers Used for RT-PCR.
 
The following primers were used
for RT-PCR: AID, sense, 5
 
 
 
-ACATCTCAGACTGGGACCTG-
3
 
 
 
 and antisense, 5
 
 
 
-TCAAAATCCCAACATACGAAATG-3
 
 
 
;
GAPDH, sense, 5
 
 
 
-CCATCACCATCTTCCAGGAG-3
 
 
 
 and anti-
sense: 5
 
 
 
-CCTGCTTCACCACCTTCTTG-3
 
 
 
; and Pax5, sense,
5
 
 
 
-TATTGTCACAGGCCGAGACTTGGCGAGC-3
 
 
 
 and anti-
sense, 5
 
 
 
-CCTCGGGCTGCAGGGCTGTAATAGT-3
 
 
 
. Quan-
tification of band intensity was performed using the NIH image
program.
 
Cloning and Sequencing of Genomic Fragments of the AID Gene.
 
Genomic fragments of the AID gene were obtained from a
mouse genomic library, TT2, using an AID cDNA probe. The
probe used for screening was generated by RT-PCR using the
following primers: sense, 5
 
 
 
-GGCACGAGCAGCACTGAAG-
CAGCC-3
 
  
 
and
 
 
 
antisense, 5
 
 
 
-GGGCGGCCGCTCAAAATC-
CCAACATACGAAATG-3
 
 
 
. The 5
 
 
 
-flanking region, exon 1,
intron 1, and exon 2 of the AID gene were sequenced using a
BigDye-terminator Cycle Sequencing Ready Reaction Kit (Ap-
plied Biosystems).
 
Luciferase Reporter Gene Transactivation Assay.
 
A series of re-
porter constructs was generated by PCR using an AID genomic
fragment as a template and cloned into a modified pGL3 basic vec-
tor. Various mutations were introduced using a site-directed mu-
tagenesis kit. 3 
 
 
 
 10
 
6
 
 BaF/3 cells were washed twice with PBS,
mixed with plasmid DNA in 400 
 
 
 
l of PBS, and electroporated at
960 
 
 
 
F, 600 V/cm. Transfectants were harvested after 18 h of in-
cubation. Luciferase assays were performed as described previously
(19). Firefly luciferase activity was normalized by 
 
Renilla
 
 luciferase
 
activity. AID promoter constructs were amplified using the 3
 
  
 
anti-
sense primer 5
 
 
 
-CTCGCGCGCTGTCCATATCGGTCTC-3
 
 
 
with the following 5
 
 
 
 primers: 0.9P, sense, 5
 
 
 
-CGGGGTAC-
CGATCAGGGTTCAGATCCC-3
 
 
 
; 0.3P sense, 5
 
 
 
-CGGGG-
TACCCCCGGGACCACACACACACA-3
 
 
 
; 0.2P, sense, 5
 
 
 
-
CGGGGTACCCGAAGGAAGTTGGACA-3
 
 
 
; 0.1P, sense,
5
 
 
 
-CGGGGTACCGACCCAACCCAGGAGG-3
 
 
 
; and 0.02P,
sense, 5
 
 
 
-CGGGGTACCGTGCTCTGTCACACAA-3
 
 
 
. The
primers used for site-directed mutagenesis were as follows: mP1,
sense, 5
 
 
 
-CTATCGATAGGTACCGAAAAAAAAAAGGAAA-
AAGATGTTGGATACCTGG-3
 
  
 
and
 
 
 
antisense 5
 
 
 
-CCAGGTA-
TCCAACATCTTTTTCCTTTTTTTTTTCGGTACCTATC-
GATAG-3
 
 
 
; mP2, sense, 5
 
 
 
-CCAGGAGGCAGATGTTAAA-
TAAATAATAATAGTGATGCTGTCGTG-3
 
  
 
and antisense,
5
 
 
 
-CACGACAGCATCACTATTATTATTTATTTAACATC-
TGCCTCCTGG-3
 
 
 
; mP3, sense, 5
 
 
 
- GTAGTGATGCTGTCG-
TAAAAAAGGAAAAAACAAGAGCAAGCTCAG-3
 
  
 
and anti-
sense, 5
 
 
 
-CTGAGCTTGCTCTTGTTTTTTCCTTTTTTAC-
GACAGCATCACTAC-3
 
 
 
; mP4, sense, 5
 
 
 
-GCAAGCTCAG-
ATTTGAATAAAAAAAAAAAGTGCTCTGTCACACAAC-
AGC-3
 
  
 
and antisense, 5
 
 
 
-GCTGTTGTGTGACAGAGCA-
CTTTTTTTTTTTATTCAAATCTGAGCTTGC-3
 
 
 
. Three
independent clones of each construct were sequenced and used for
experiments. The primers used for CR1 and CR2 fragments were
as follows: Bam-CR1F, 5
 
 
 
- CGGGATCCCTGTGTTGCTAG-
AGATAGGAAG-3
 
 
 
; Bam-CR1R, 5
 
 
 
-CGGGATCCCCAAA-
CGGAAGTGAGCTCAAGT-3
 
 
 
; Bam-CR2F, 5
 
 
 
-CGGGATC-
CGGGTCCGAGAGAAATGCATGAG-3
 
 
 
; Bam-CR2R, 5
 
 
 
-
CGGGATCCATTATGAAGGAAAGGTATCCTT-3
 
 
 
.
 
Immunoblot Analysis.
 
Cell extracts were prepared from pri-
mary B cells or 293T cells transfected with indicated expression
vectors for 48 h, and protein amounts were quantified with Mi-
cro BCR Protein Assay Reagent (Pierce Chemical Co.). For im-
munoblotting, we used anti-E47 antibody (G127–32; BD Bio-
sciences), anti-Pax-5 (N19; Santa Cruz Biotechnology, Inc.), and
anti–
 
 
 
-actin (AC74; Sigma-Aldrich).
 
Electrophoretic Mobility Shift Assay.
 
Nuclear extracts of splenic
B cells were prepared after incubation with LPS (Sigma-Aldrich)
plus IL4 (Peprotech) (18) and protein amounts quantified with
Micro BCA Protein Assay Reagent (Pierce Chemical Co.). Dou-
ble stranded oligoprobes were end labeled using T4 polynucle-
otide kinase and purified over a Sepharose G50 column. Nuclear
extracts and labeled oligoprobes were used in a gel shift assay as
described (17) with slight modifications. For the super shift ex-
periment, nuclear extract was incubated with 5 
 
 
 
g of a goat
anti–mouse Pax5 antibody (N-19; Santa Cruz Biotechnology,
Inc.), designated antibody 1, or a mouse anti-Pax5 antibody
(BD610862; BD Biosciences), designated antibody 2, or a mouse
anti-E2A antibody (Yae; Santa Cruz Biotechnology, Inc.) for 20
min at room temperature before the labeled probe was added. The
sequences of the oligoprobes were as follows: CD19 (competitor),
5
 
 
 
-CCCCCGCAGACACCCATGGTTGAGTGCCCTCCAG-
GCCCCTGCC-3
 
 
 
 and 5
 
 
 
-CAGGCAGGGGCCTGGAGGGC-
ACTCAACCATGGGTGTCTGCGG-3
 
 
 
; Pa3, 5
 
 
 
-GATGCT-
GTCGTGGGGGAGGAGCCCACAAGAGCAAGCTCAG-3
 
 
 
and 5
 
 
 
-CTGAGCTTGCTCTTGTGGGCTCCTCCCCCACG-
ACAGCATC-3
 
 
 
; Pa3-m1, 5
 
 
 
-GATGCTGTCGTAAAAAAGG-
AGCCCACAAGAGCAAGCTCAG-3
 
 
 
 and 5
 
 
 
-CTGAGCTTG-
CTCTTGTGGGCTCCTTTTTTACGACAGCATC-3
 
 
 
; Pa3-m2,
5
 
 
 
-GATGCTGTCGTGGGGGAGGAAAAAACAAGAGCAA-
GCTCAG-3
 
 
 
 and 5
 
 
 
-CTGAGCTTGCTCTTGTTTTTTCCT-
CCCCCACGACAGCATC-3
 
 
 
; Pa3-m3, 5
 
 
 
-GATGCTGTCG-
TAAAAAAGGAAAAAACAAGAGCAAGCTCAG-3
 
 
 
 and 5
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CTGAGCTTGCTCTTGTTTTTTCCTTTTTTACGACAG-
CATC-3
 
 
 
; Pa3-m4, 5
 
 
 
-GATGCTGTCGTTTTTTAGGAGCC-
CACAAGAGCAAGCTCAG-3
 
 
 
 and 5
 
 
 
-CTGAGCTTGCTCT-
TGTGGGCTCCTAAAAAACGACAGCATC-3
 
 
 
; Pa3-m5, 5
 
 
 
-
GATGCTGTCGTGGGGGAGGATTTTACAAGAGCAAGC-
TCAG-3  and 5 -CTGAGCTTGCTCTTGTAAAATCCTC-
CCCCACGACAGCATC-3 ; Pa3-m6, 5 -GATGCTGTCGT-
TTTTTAGGATTTTACAAGAGCAAGCTCAG-3 ; and 5 -
CTGAGCTTGCTCTTGTAAAATCCTAAAAAACGACAG-
CATC-3 ; oct, 5 -TGTCGAATGCAAATCACTAG-3  and 5 -
TTCTAGTGATTTGCATTCGA-3 ; and  E5 (competitor), 5 -
TCGAAGAACACCTGCAGCAGCT-3  and 5 -TAGAGCTG-
CTGCAGGTGTTCTT-3 . Quantification of intensity was per-
formed using a Bio Imaging Analyzer MacBAS (FUJIFILM).
Chromatin Immunoprecipitation. ChIP assays were performed
according to the protocol for the ChIP assay kit (Upstate Biotech-
nology; http://www.upstate.com/misc/protocols.asp?prot chips)
and as reported (20) with slight modifications. Splenic B cells (106)
were subjected to chromatin cross-linking by addition of formalde-
hyde to the medium at a final concentration of 1% and incubation
for 2 min at 37 C. The cells were then washed with ice cold PBS,
resuspended in 0.2 ml of SDS-lysis buffer (50 mM Tris, pH 8.0, 1%
SDS, 10 mM EDTA, 10  g/ml aprotinin, 10  g/ml leupeptine, 1
mM PMSF), and incubated on ice for 10 min. Cell lysates were
sonicated to reduce the DNA length to between 200 and 1,000 bp,
and debris was removed by centrifugation. Sonicated lysates were
then diluted by adding 1.8 ml of ChIP dilution buffer (50 mM Tris,
pH 8.0, 167 mM NaCl, 1.1% Triton X-100, 0.11% sodium deoxy-
cholate, 10  g/ml aprotinin, 10  g/ml leupeptine, 1 mM PMSF)
and precleared according to the protocol of Upstate Biotechnology.
Precleared lysates were incubated overnight at 4 C with 6  g of
the  following antibodies. For E2A, mixed anti-E2A antibodies
(BD554077 [BD Biosciences] and V18X [Santa Cruz Biotech])
were used. For Pax5, anti-Pax5 antibody (C-20; Santa Cruz Bio-
tech) was used. For acetylated histone H3,  -acetyl H3 antibody
(Lys9, Lys14; Upstate Biotechnology) was used. As a control, nor-
mal goat IgG (for Pax5) or mixed normal mouse and goat IgG (for
E2A) or normal rabbit IgG (for acetylate H3) was used (Santa Cruz
Biotechnology). Each immunocomplex was recovered with protein
G–Sepharose beads (Amersham Biosciences). Each precipitate was
washed serially with 1-ml aliquots of the following wash buffers.
Low salt buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM
EDTA, 2% Triton X-100, 0.2% SDS, 0.2% sodium deoxycholate),
high salt buffer (50 mM Tris-HCl, pH 8.0, 500 mM NaCl, 1 mM
EDTA, 2% Triton X-100, 0.2% SDS, 0.2% sodium deoxycholate),
LiCl wash buffer (250 mM LiCl, 0.5% Nonidet P-40, 0.5% sodium
deoxycholate, 1 mM EDTA, 10 mM Tris-HCl, pH 8.0), and TE
buffer, pH 8.0. Immunocomplexes were next eluted from beads us-
ing elution buffer (10 mM Tris-HCl, pH 8.0, 5 mM EDTA, 300
mM NaCl, 0.5% SDS), and the cross-linking was reversed by incu-
bation in this buffer at 65 C for 16 h. The samples were then treated
with RNase A (20  g/ml, 30 min, 37 C) followed by proteinase K
(50  g/ml, 1 h, 55 C), extracted with phenol-chloroform, and pre-
cipitated with ethanol in the presence of carrier glycogen. Pellets
were resuspended in 50  l of TE buffer for input DNA and 20  l of
TE buffer for ChIP DNA. Serial dilutions of DNAs were prepared
in 25  g/ml sonicated pBSKS. Specific sequences in the immuno-
precipitates were detected by PCR in which product yield was
dependent on input DNA dose. Primer pairs with the following
sequences were used: AID-CR2 region, sense, 5 -CGGGATC-
CGGGTCCGAGAGAAATGCATGAG-3 , antisense, 5 -CGGG-
ATCCATTATGAAGGAAAGGTATCCTT-3 ; AID promoter,
sense, 5 -CGGGGTACCCGAAGGAAGTTGGACA-3  and anti-
sense, 5 -CTCGCGCGCTGTCCATATCGGTCTC-3 ; mb-1,
sense, 5 -CACGCACTAGAGAGAGACTCAA-3  and antisense,
5 -CCGCCTCACTTCCTGTTCAGCCG-3 ; CD3 , sense, 5 -
GGCCCGGATTTCCTCAGTTA-3  and antisense, 5 -GCCAT-
AGTAGGATGAATGAG-3 ; I , sense, 5 -CAAGGAGACCT-
GGGATCAGACGATGGAG-3   and  antisense, 5 -TCTGCCT-
CAGTGCCCTCAGCTAAAAG-3 . Intensity was quantified
using the NIH image program.
Results
Reduced AID Gene Expression in Id2-overexpressing B
Cells. It has been shown that enforced expression of Id2
blocks CSR completely (9). To gain insight into the mo-
lecular mechanisms underlying CSR regulation, we ana-
lyzed the levels of expression of AID, which is essential for
CSR (12), in Id2-overexpressing B cells. Id2 cDNA was
cloned into the pMXIRES-hCD4 retroviral vector (21),
which enabled us to trace Id2 expression by monitoring the
surface expression of human CD4 (Fig. 1 a). Splenic B cells
were infected with the virus by spin infection (14). After
3 d of stimulation with LPS plus IL4, Id2-expressing B cells
were purified using MACS by virtue of CD4 expression.
Figure 1. Effect of enforced expression of Id2 on AID transcription. (a)
A diagram of the Id2 retrovirus construct. Surface expression of truncated
human CD4 was used as the marker of infected cells. (b) The expression
levels of AID in splenic B cells stimulated in vitro. RNAs from Id2-
transduced and control populations were subjected to RT-PCR analysis.
(c) The expression levels of AID in splenic B cells stimulated in vitro.
RNAs from Id2 /  and Id2 /  B cells were subjected to RT-PCR analysis.
One of three independent experiments is shown. Fivefold serial dilutions
of cDNAs were amplified for the indicated transcripts. GAPDH was used
as an internal control. (d) Time course analysis of the Pax5 and E2A proteins
in in vitro–activated splenic B cells. Each lane contains the extract from
the equal cell numbers (2   106 cells). (e) Time course analysis of the AID
expression in in vitro–activated splenic B cells. One of three independent
experiments is shown. Fivefold serial dilutions of cDNAs were amplified
for the indicated transcripts. GAPDH was used as an internal control.T
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RNA was extracted from them and subjected to RT-PCR
analysis. As shown in Fig. 1 b, a fivefold reduction of AID
expression was observed in Id2-transduced cells. This ob-
servation suggests that the inhibitory effect of Id2 on CSR
is in part the result of repression of AID expression.
To determine whether this inhibitory effect of Id2 on
AID expression indeed works in activated B cells in vivo,
we examined the AID expression in Id2 /  spleen cells.
Id2 /  spleen cells expressed fivefold more AID transcripts
than Id2 /  spleen cells (Fig. 1 c). These data further sup-
port the possibility that Id2 functions as a negative regulator
of AID expression in vivo. E2A and Pax5 are strong candi-
dates as inducers of AID expression because increased
amounts of these factors are observed upon B cell activa-
tion. To monitor the expression of AID mRNA during
switch induction of primary B cells, RT-PCR analysis was
performed after cytokine treatment. AID mRNA was un-
detectable initially and was induced after 2 d of in vitro cul-
turing (Fig. 1 e). To compare the kinetics of AID expres-
sion with the levels of E2A and Pax5 proteins, Western
blotting was performed. About fivefold induction of E47
and sevenfold induction of Pax5 were observed at 2 d
Figure 2. Conservation of AID promoter sequence in mice and humans.
(a) Dot matrix sequence comparisons of the sequences of the mouse and
human AID 5  upstream region, exon 1, intron 1, and exon 2 using a
window with 33 of 50 matches. A schematic diagram of the putative regula-
tory regions of the AID genes in mice and humans is shown below the
matrix. The open boxes indicate exons. Underlines indicate conserved
sequences. (b) Alignment of 5 -flanking conserved sequences of the AID
genes of mice and humans. Vertical lines indicate conserved nucleotides
in the two species. The underlined sequence is the first ATG. The arrow
indicates the transcription initiation site. (c) Alignment of CR1 conserved
sequences of the AID genes of mice and humans. Vertical lines indicate
nucleotides conserved between the two species. (d) Alignment of CR2
conserved sequences of the AID genes of mice and humans. Vertical lines
indicate nucleotides conserved between the two species. The open boxes
indicate the E-box sequence.T
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postactivation (Fig. 1 d). In addition to this observation,
E2A and Pax5 are known to bind and be antagonized
by Id2. These data support the idea that Id2 represses
AID expression through antagonizing E2A and Pax5 activ-
ities.
Potentially Important Sequences in 5 -flanking Region and
First Intron of the AID Gene. To elucidate the mechanism
of the transcriptional regulation of AID, we isolated geno-
mic DNA fragments of the AID gene containing the 5 -
flanking region and first and second exons. Because cross
species conservation of regulatory region sequences is com-
mon, we first performed homology plot analysis of se-
quences in the 5 -flanking region and the first intron for
mice and humans. As shown in Fig. 2 a, a strikingly ho-
mologous region spanning  400 bp was found in the re-
gion upstream of the first ATG codon, and it included a
putative transcription initiation site (shown in Fig. 2, a and
b) from which the most abundant transcripts were pro-
duced (not depicted). There were two additional homolo-
gous regions, which we designated CR1 and CR2, in the
first intron (Fig. 2 a). An alignment of the murine and hu-
man conserved sequences is shown in Fig. 2, b, c, and d.
Two E-boxes, the consensus sequence for E2A binding,
were present in CR2 region in both humans and mice (Fig.
2 d). This observation further supports the involvement of
E2A in AID expression.
Transactivation of AID Promoter by Pax5. To confirm
that the 900-bp 5  fragment containing the conserved
CR1 and CR2 regions was sufficient to direct develop-
mental stage-specific AID expression, reporter assays were
performed using the M12 B cell line, in which the endog-
enous AID gene is expressed, and the BaF/3 pro–B cell
line, in which it is not (not depicted). We subcloned a
0.9-kb AID promoter region fragment including the CR1
and CR2 fragments into the pGL3 plasmid, resulting in
construct 0.9P-CR1 CR2, and analyzed the promoter
activity of this construct in both cell lines. The results
shown in Fig. 3 a demonstrate that 0.9P-CR1 CR2 was
sufficient to direct expression specifically in the M12 cell
line; 0.9P-CR1 CR2 was at least fivefold better ex-
pressed in M12 cells than BaF/3 cells. This observation is
Figure 3. Transcriptional activation of the putative AID promoter by
Pax5. (Left) Schematic diagrams of reporter constructs containing no
enhancer or promoter (Basic-pGL3), only SV40 promoter (SV40-pGL3),
all the conserved sequences (0.9P-CR1 CR2), all the conserved sequences
with deleted E-boxes (0.9P-CR1 CR2 E), promoter only (0.9P), pro-
moter plus CR1 (0.9P-CR1), promoter plus CR2 (0.9P CR2), various
promoter deletions (0.3P, 0.2P, 0.1P, and 0.02P), various potential Pax-
binding site mutations (0.1P-mPa1, 0.1P-mPa2, 0.1P-mPa3, and 0.1P-
mPa4). (a, right) BaF/3 cells or M12 cells were transfected with AID–
luciferase constructs (20  g). All assays were independently performed five
times in duplicate. Luciferase activity is the relative luminescence units
normalized by Renilla luciferase activity. (b, right) BaF/3 cells were trans-
fected with AID–luciferase constructs (20  g) or Gl  promoter constructs
(20  g) in the absence (black bars) or presence of pcDNA-Pax5 (15  g)
(black bars) or pcDNA-E47 (15  g) (white bars). Immunoblot analysis of
Pax5 and E2A proteins in 293T cells transfected with indicated expression
vectors. (c) BaF/3 cells were transfected with AID–luciferase constructs
(20  g) in the absence (black bars) or presence (black bars) of pcDNA-
Pax5 (15  g). (d) BaF/3 cells were transfected with various deletion AID–
luciferase constructs (20  g) in the absence (black bars) or presence of
pcDNA-Pax5 (15  g) (black bars). (e, top column) Schematic representation
of AID promoter. Boxes indicate putative Pax5-binding sequences
(Pa1–Pa4). (e, left) Schematic diagrams of the mutated promoter constructs.
Arrowheads indicate the mutations introduced into putative Pax5-binding
sites Pa1–Pa4. (e, middle right) BaF/3 cells were transfected with AID–
luciferase constructs (20  g) in the absence (black bars) or presence (black
bars) of pcDNA-Pax5 (15  g). (e, lower right) M12 cells were transfected
with the indicated AID–luciferase constructs (20  g). Luciferase activity is
the relative luminescence units normalized by Renilla luciferase activity. All
assays were independently performed six times in duplicate.T
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consistent with the homology plot analysis. Since Id2 is a
negative regulator of E protein (22) and Pax5 (4) function,
reduced activity of E2A or Pax5 products may directly
contribute to the loss of AID expression in cells with en-
forced Id2 expression. To test this possibility, the effects of
these factors on transactivation of the 0.9P-CR1 CR2
construct were determined using BaF/3 cells. Pax5, but
not E47, an E2A gene product, indeed induced transacti-
vation by a factor of eleven from the WT promoter (Fig. 3
b, top column). This effect was consistent with the results
shown in Fig. 3 a in which mutation of the E-boxes had
no effect on transcription from the 0.9P-CR1 CR2 con-
struct in M12 cells, which have high E2A activity (not de-
picted). To determine the expression of each factors, we
performed Western blot analysis using transiently trans-
fected 293T cells. As shown in Fig. 3 b, bottom column,
these plasmids worked equally. In addition, E47 activity in
BaF/3 cells was confirmed using E47 expression vector
and  I promoter reporter construct, which is responsive to
E47 and Pax5 (Fig. 3 b, middle column and previously re-
ported) (23). Again, Pax5 but not E47 only has a potential
to induce AID expression in BaF/3 lines. To further iden-
tify the Pax5-responsive element, 0.9P (promoter only),
0.9P-CR1 (promoter plus CR1 fragment), and 0.9P-CR2
(promoter plus CR2 fragment) were examined. As shown
in Fig. 3 c, all the reporters were responsive to Pax5, indi-
cating that a Pax5-binding sequence may exist in the 5 -
flanking region of the AID gene. In addition to this obser-
vation, CR1 and CR2 seems to work as a tissue-specific
repressive element of the AID gene because these regions
have a repressive effect in BaF/3 cells (Fig. 3 c) but not in
M12 cells (not depicted). We sometimes observed that
constructs without CR1 or CR2 have higher promoter
activities (Fig. 3 d) than those with CR1 or CR2, which
have consistently almost no activities, in BaF/3 cells with-
out Pax5. To further delineate the Pax5-responsive ele-
ment within this region, various deletion constructs were
examined. As shown in Fig. 3 d, the 0.02P promoter lost
the responsiveness to Pax5, indicating that a Pax5-binding
sequence may exist between  122 and  22 bp from the
initiation site. We found four putative Pax5-binding sites
(Pa1-Pa4) within this region (24) and analyzed the pro-
moter activity of constructs mutated in each of these sites
(Fig. 3 e). As shown in Fig. 3 e, the third site (Pa3) was in-
dispensable for transactivation by Pax5, since Pax5 was un-
able to induce transactivation of the 0.1P-mPa3 promoter.
To confirm that mature B cells actually use this element
for AID expression, the promoter activity of each mutant
construct was analyzed using the mature B cell line M12,
which expresses both Pax5 and AID. Again, the third site
(Pa3) was indispensable for proper expression of AID,
since transactivation was reduced using the 0.1P-mPa3
promoter in M12 cells in which Pax5 activity is high (un-
published data; Fig. 3 e).
Pax5 Binds the AID Promoter. To determine whether
Pax5 binds to the P3 site in the AID promoter, we per-
formed electrophoretic mobility shift assays (EMSAs) using
AID promoter oligonucleotides bearing the P3 site. WT
and mutant oligonucleotides used in this assay are shown in
Fig. 4 a, top column. Nuclear extracts prepared from WT
Figure 4. Binding of Pax5 to the AID promoter. (a, top column, top panel) Pax5-binding sequence in the mb-1 promoter. The DNA sequences of
the probes used in this assay (b) are shown. Pa3 represents the WT sequence. Underlined sequences of the WT P3 probe were changed as noted (Pa3-m1
to P3-m6). (a, bottom column) The DNA sequences of the probes used in this assay (c) are shown. CR2E represents the WT sequence. Underlined
sequences of the WT CR2E probe were changed as noted (CR2E-m1 to P3-m3). (b) EMSA of nuclear extracts from splenic B cells of Id2 /  and
control mice treated with 20  g/ml LPS plus 10 ng/ml IL-4 for 3 d using the probes shown in panel a. The asterisk indicates the Pax5-containing
complex. The arrowhead indicates a nonspecific band. An Oct probe was used as an internal control. One of three independent experiments is shown.
(c) EMSA of nuclear extracts from splenic B cells of Id2 /  and control mice treated as described in panel b using the probes shown in panel a. The
arrows indicate the E2A-containing complex. One of six independent experiments is shown. (d) The levels of Pax5 or E2A proteins and Pax5 transcripts.
In vitro–stimulated B cells from Id2 /  and Id2 /  mice were subjected to Western blotting or RT-PCR. One of three independent experiments is
shown. Fivefold serial dilutions of cDNAs were amplified for the indicated transcripts. GAPDH or  -actin were used as an internal control. (d) Nuclear
extracts prepared from hCD4-positive cells obtained as described in Fig. 1 were analyzed by EMSA using the P3 probe.T
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B cells after stimulation with LPS and IL4 were tested for
binding to these oligonucleotides. One complex was de-
tected, and inclusion of Pax5 in this complex was verified
by using a specific antibody against Pax5 (Fig. 4 b, lanes 11
and 12) and competitive oligonucleotides to which Pax5
binds (Fig. 4 b, lane 10). The binding activity was reduced
when mutant oligonucleotides, Pa3-m1 through Pa3-m6,
were used (Fig. 4 b). On the other hand, the binding activ-
ity of Pax5 was more prominent when extract from Id2 / 
B cells was analyzed. The extract from Id2 /  B cells
formed about twice as much binding complex with this
probe as the extract from control cells (Fig. 4 b, lanes 2 and
3). The most slowly migrated band may not contain Pax5
because this band always disappears using normal IgG (Fig.
4 b, lanes 13–15). RT-PCR demonstrated no significant
difference between the expression of Pax5 in splenic B cells
with the two different genotypes, suggesting that Id2 does
not affect the expression of Pax5 (Fig. 4 d). As expected,
Western blotting demonstrated no significant difference in
the levels of Pax5 proteins in activated B cells with the two
genotypes (Fig. 4 d). To further determine the actual con-
tribution of E2A in AID expression in Id2 /  B cells, we
performed EMSAs using AID enhancer oligonucleotides
bearing two E-boxes (Fig. 4 c). WT and mutant oligonu-
cleotides used in this assay are shown in Fig. 4 a, bottom
column. The extract from Id2 /  B cells formed  1.2-fold
more binding complex with this probe as the extract from
control cells. Such a slight difference is unexpected, since
we previously detected more prominent difference using
an   promoter as a probe (23). Such discrepancy of E2A-
containing bands will be produced by the context-depen-
dent differences in complex formation. Western blotting
demonstrated no significant difference in the levels of E2A
proteins in activated B cells with the two genotypes (Fig. 4
d). Collectively, these data further support the idea that Id2
acts as an antagonist against Pax5 and E2A within AID lo-
cus. To further determine whether Id2 indeed functions as
a dominant-negative regulator of Pax5 products, nuclear
extracts were prepared from Id2-overexpressing B cells and
analyzed by EMSA. As expected, the level of Pax5–DNA-
binding complex was reduced in the extract from Id2-
transduced cells by a factor of three (Fig. 4 e). This Pax5-
containing complex may contain other factors, since it
migrates slowly when compared to the band using the
CD19 site as a probe. Unfortunately, we couldn’t identify
any other components of this complex. Further studies are
required to identify the other factors involved in this com-
plex. In addition to these observations, the binding activity
of Pax5 was more prominent when the CD19 site was used
as a probe. Compared with the Pa3 site,  98-fold en-
hancement was observed (Fig. 4 b, lanes 1 and 3). This data
indicated that the Pa3 site is the weak binding site of Pax5.
Recruitment of Pax5 to the AID Promoter in Activated B
Cells. Next, we examined whether Pax5 indeed binds to
the AID promoter in activated B cells by a chromatin im-
munoprecipitation (ChIP) assay using  -Pax5 antiserum.
Splenic B cells were isolated and stimulated in vitro with
LPS plus IL-4. Serially diluted DNA samples isolated from
the input,  -Pax5–bound, and control antibody-bound
fractions were tested by PCR to analyze the AID promoter.
AID promoter DNA was recovered from  -Pax5–bound
but not from  -E2A–bound chromatin after 2 d of cultur-
ing, providing direct evidence that Pax5 but not E2A occu-
pies the AID promoter in activated B cells (Fig. 5 a). On
the other hand, the CR2 fragment, which contains two
E-boxes, was recovered from  -E2A–bound chromatin at
the same level at all the time points examined (Fig. 5 a). In
contrast, the CR2 fragment was also recovered from
 -Pax5–bound chromatin after 2 d of culturing (Fig. 5 a).
For the positive and negative control loci to Pax5, mb-1 and
CD3  locus were selected. As shown in Fig. 5 a, mb-1 pro-
moter but not CD3  was recovered from  -Pax5–bound
chromatin at the all time points examined. For the positive
control for E2A, the  Ip locus was used. As expected,  Ip
promoter was recovered from  -E2A–bound chromatin af-
ter 2 d of culturing (Fig. 5 a). Collectively, these data fur-
Figure 5. Recruitment of Pax5 to the AID promoter in activated B
cells. (a) ChIP analyses at the indicated sites. Fivefold serial dilutions of
input DNA and DNAs immunoprecipitated with anti-E2A, anti-Pax5,
anti–acetylated histone H3, and control (antibodies) Abs were analyzed
by PCR. One of three independent experiments is shown. (b) Pax5-
induced  endogenous AID expression in BaF/3 cells. Pax5 or E47 or
empty vectors (pMX-IREShCD4) were introduced into BaF/3 cells via
retroviral transfer. RNAs prepared from hCD4-positive cells were analyzed
by RT-PCR. One of five independent experiments is shown.T
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ther support the important role of Pax5 in AID expression,
considering the fact that AID expression was induced after
2 d of in vitro culturing as shown in Fig. 1 d.
Ectopic Expression of Pax5 Activates Endogenous AID Tran-
scription in BaF/3. Pax5 clearly transactivated the AID re-
porter constructs in transient transfection assays in BaF/3
cells. To test whether expression of Pax5 in non-AID–
expressing cells can activate the transcription of the endog-
enous AID gene, BaF/3 cells were retrovirally transduced
with Pax5 or E2A. RT-PCR showed that BaF/3 cells
transduced with Pax5 indeed produced the AID transcript
(Fig. 5 b). In contrast, BaF/3 cells transduced with E2A did
not (Fig. 5 b). We further confirmed that Id2 has an antag-
onizing effect on AID expression induced by Pax5 in BaF/3
cells (not depicted). These observations are consistent with
the results of the reporter assay, which showed that Pax5 is
required for the activation of the AID promoter, and with
the loss of AID expression in Id2-transduced B cells. In
summary, these results demonstrate the essential and selec-
tive role of Pax5 in directing tissue- and stage-specific en-
dogenous AID expression.
Discussion
Increasing evidence has suggested that AID expression
alone is sufficient to induce SHM and CSR in B cell hy-
bridomas, T cells, and fibroblasts (25–27). These observa-
tions also indicate that AID could act as a mutator if the
negative regulation systems controlling AID expression
were disrupted. On the other hand, AID is the only known
factor indispensable for CSR and SHM (12), both of which
are required for the proper functioning of B cells to pro-
duce high affinity antibodies with different effector func-
tions (13). In normal B cells, AID expression is tightly reg-
ulated in an activation-dependent manner in conditions
under which SHM and CSR take place (28). In this report,
we clearly demonstrated that the AID promoter is a direct
target of Pax5 in activated B cells. Lineage-specific tran-
scription factors that act as positive regulators of AID ex-
pression are very likely to carry out one of the mechanisms
regulating the lineage-specific expression of AID. Such a
scenario would be a simple and reasonable strategy for ob-
taining lineage-specific expression. Within the lymphoid
lineage, Pax5 is clearly restricted to B cells. On the other
hand, what is the molecular switch sensing the activation
stimuli and inducing the expression of the AID gene? As
shown in this report, the level of Pax5 protein was in-
creased 2 d after stimulation (10). This time course was in
accord with that of AID expression. Furthermore, we have
identified several other Pax5-binding sites within the regu-
latory regions of the AID gene (unpublished data). How,
then, does the AID locus sense the augmentation of Pax5
in activated B cells? This might be achieved by low affinity
binding sites within the AID regulatory regions. As shown
in this paper, Pax5 occupancy at the AID locus could be
detected only from the 2-d time point onward. In contrast,
Pax5 occupancy at the mb-1 locus can be detected in both
resting and activated B cells (Fig. 5 b). These observations
are consistent with a recent study using floxed Pax5 mice
in which the serum levels of isotype-switched antibodies
were shown to be decreased in Pax5F/  CD19-cre mice
(8). On the other hand, E47 occupancy at the AID locus
was detected in both resting and activated B cells. This ob-
servation suggests that E47 may play a more general rather
than B cell activation–dependent role in regulating the
AID locus.
We also demonstrated that Id2 acts as a negative regula-
tor of AID expression in activated B cells. The Id2 protein
acts as a key regulator of cell fate determination. In Id2 / 
mice, the number of NK cells is greatly reduced, and LNs,
Peyer’s patches, and NALT are absent due to the loss of
CD3 CD4 CD45  cells (29, 30). Previous reports have
suggested that Id proteins play roles in B cell differentiation
and maturation (31). However, Id2 /  mice show normal
distributions of B cell populations in the BM and spleen
(unpublished data). However, upon B cell activation Id2
plays a key role in antagonizing the Pax5 and E2A activi-
ties, both of which are required for proper B cell differenti-
ation (5–7). In activated B cells, the levels of E2A proteins
and Pax5 transcripts are highly augmented, and antagonists
of these factors inhibit CSR (9–11, 32). The results suggest
the involvement of E2A and Pax5 in CSR. Among them,
Pax5 directly induces AID expression through a Pax5-
binding sequence that exists in the putative enhancer/pro-
moter of the AID gene (Fig. 6). The importance of Pax5
and Id2 in regulating AID expression was further supported
by our observation that enforced expression of Pax5- but
not E47-induced endogenous AID expression in BaF/3
cells, and this effect was cancelled by additional induction
of Id2. In contrast, whether E2A proteins are involved in
the regulation of AID expression is still unclear. A recent
report from Murre’s group demonstrated that E2A is a pos-
itive regulator of AID gene expression (33). We were not
able to reproduce such effects in our system probably be-
cause of the difference in cell lines and experimental condi-
tions used. In considering the characters of the two cell
lines used, E2A might require other factors, such as Pax5,
to induce AID expression. In this context, Pax5 and E2A
may act in synergy in regulating AID expression. Further
experiments will be required to examine this possibility. In
any case, Id2 plays a key role in the negative regulation of
AID expression, as shown by the AID overexpression in
Id2 /  B cells. There was no difference between Id2 / 
and control B cell populations in the levels of Pax5 proteins
or transcripts. However, the Pax5–AID promoter–binding
complex was augmented in Id2 /  mice. Conversely, the
Pax5-binding complex was reduced in Id2-transduced
cells. Together, these findings suggest that the repressive ef-
fect of Id2 on AID expression was the result of antagoniz-
ing the effect of Pax5 in activated B cells. Interaction be-
tween Id2 and Pax5 as biochemical nature in vitro is
actually weak and may not be direct in vivo. Binding to
Pax5 may not be the only way to antagonize Pax5 activity
by Id2. However, Pax5 antagonizing activity of Id2 wasT
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further supported by the observation that the repressive ef-
fect of TGF- 1 on CD19 expression was lost in Id2 / 
mice (unpublished data). Further studies are required to re-
veal the actual mechanism involved in this antagonism.
However, such regulation seems quite possible considering
the mechanism of repression of the AID gene after activa-
tion. Recent studies have indicated that Blimp-1 is re-
quired for the differentiation of B cells into plasmacytes.
Transcription of Blimp-1 is induced at the later stages of in
vitro culturing of primary B cells (10, 32), and one of its
most important functions is to repress Pax5 expression (10).
Interestingly, Id2 is thought to be the target whose expres-
sion is induced by Blimp-1 (32). Collectively, these pub-
lished observations and our findings in the present study
suggest that after B cell activation Blimp-1 works as a mo-
lecular switch to repress AID expression through repressing
and antagonizing Pax5 activity.
We could not detect augmentation of AID expression by
forced expression of either Pax5 or E2A in activated pri-
mary B cells using a retroviral transfection system (unpub-
lished data). There are possible but not mutually exclusive
reasons for this. First, there might be a safeguard or feed-
back system to ensure the activities of Pax5 and/or E2A do
not elevate more than normal. Id2 could be involved in
this system since Id2 /  B cells have elevated activities of
E2A and Pax5. Second, other than a simple amount, there
might be a crucial timing and/or order of activation, which
we could not control by a retroviral expression system, of
these factors to activate AID gene expression. Forced ex-
pression of Id2 using the same system could repress AID
expression, as shown here, since unregulated overexpres-
sion could antagonize E2A and Pax5 throughout the acti-
vation process. A recent report from Murre’s group
showed a somewhat different result in which enforced ex-
pression of E2A enhances the AID expression by a factor of
two in activated primary B cells (33). This result was ob-
tained by an experimental system that induced very rapid,
vast enhancement of E2A activity in the nuclei. They used
E2A fused to estrogen receptor accumulating in cytoplasm
and then forced the accumulated E2A fusion protein to
move into nuclei almost at once by 4-hydroxytamoxifen
treatment. Such a procedure might enhance the effective
E2A activity by breaking the feedback negative regulation
system. Further investigations are necessary to elucidate
fine molecular mechanisms to induce AID gene expression
during B cell activation.
Our results indicate that modulating the relative abun-
dance of Pax5, E2A, and Id proteins provides a mechanism
for subtle regulation of the effects of Pax5 and E2A in B
cell activation (Fig. 6). The differential activities of these
factors determine whether the AID locus is activated and its
level of transcription. Such decision-making processes may
occur at many steps of cell differentiation and function. Ac-
tually, the IgE locus is also regulated under the control of
these factors in activated B cells (23, 34, 35). E2A and Pax5
indeed exist at the   germline promoter in IL-4–stimulated
B cells (Fig. 5 a and unpublished data). IL-4 stimulates tran-
scription of the unrearranged  1 and   heavy chain loci
(germline transcription, GLT) and induces CSR to both
isotypes, but the frequency of IgE CSR is strictly regulated
at a lower level. In contrast, in Id2 /  B cells, CSR to IgE
is enhanced without affecting IgG1. This enhanced CSR
to IgE solely depends on the augmentation of E2A and
Pax5 activities, which induce   GLT and CSR via E-boxes
and a Pax5-binding site in the   germline promoter. In
WT B cells, Id2 is induced by TGF- 1 and negatively reg-
ulates CSR to IgE. This suppression does not occur in Id2-
deficient B cells (23). Thus, the Pax5-E2A-Id system seems
to work as a molecular switch in the B cell activation pro-
gram to regulate specific transcription of various loci. Upon
activation, a breakdown of repression is achieved by aug-
mentation of Pax5 and E2A activities. Thus, Pax5 and E2A
Figure 6. Model for the regulation
of AID and IgE gene expression by
E2A, Pax5, and Id2.T
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work as a transcriptional switch in B cell activation as ob-
served at the AID and IgE loci. Moreover, Id proteins may
play widespread regulatory roles in regulating gene expres-
sion and differentiation, including in activated B cells.
Although the augmentation of AID expression was ob-
served in Id2 /  mice, the rate of SHM is not enhanced
(unpublished data) and the enhancement of CSR is only
observed for IgE (23). These data indicate that other regu-
latory mechanism(s) to prevent harmful effects of AID must
exist in activated B cells. Further studies will be required to
elucidate the molecular mechanisms involved in this regu-
latory program.
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